From Bench to Bedside: A Comprehensive Study on Pardaxin Peptide's Antimicrobial Effect on Escherichia coli, Including Clinical Isolates

Document Type : Original Articles

Authors

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.32592/ARI.2024.79.5.963

Abstract

Escherichia coli is a common cause of urinary tract infections and it has shown increasing resistance to available antimicrobial agents. Antimicrobial peptides, such as Pardaxin, offer a potential alternative to antibiotics due to their ability to disrupt the cell membrane of bacteria through their interaction with the lipid bilayer. This mode of action provides an advantage by reducing the likelihood of resistance development compared to traditional antibiotics that target specific cellular processes. The objective of this study was to assess the antimicrobial efficacy of the Pardaxin peptide against both standard and clinical strains of E. coli. E. coli ATCC 25922 was used as the standard strain, and 20 samples of E. coli derived from patients were included in the study. Isolation and identification of E. coli were done by using enrichment media, selective media, and biochemical tests. Bacterial culture was conducted on Mueller-Hinton agar, and the antimicrobial effect of the Pardaxin peptide was assessed using classic disk diffusion tests. During the disk diffusion test, we observed a distinct area of no growth surrounding the Pardaxin material for both the standard and clinical strains. In the microdilution test, the minimum inhibitory concentration of Pardaxin was 390 µg/ml for the clinical strain and 450 µg/ml for the standard strain, which is an acceptable concentration compared to the concentration of 500 µg/ml erythromycin and indicates the antibacterial properties of Pardaxin on E. coli. The results of this study provide evidence for the antimicrobial properties of the Pardaxin peptide against both standard and clinical strains of E. coli.

Keywords

Main Subjects

References

  1. Kaper JB, Nataro JP, Mobley HL. Pathogenic escherichia coli. Nature reviews microbiology. 2004;2(2):123-40.
  2. Poirel L, Madec J-Y, Lupo A, Schink A-K, Kieffer N, Nordmann P, et al. Antimicrobial resistance in Escherichia coli. Microbiology spectrum. 2018;6(4).
  3. Paitan Y. Current trends in antimicrobial resistance of Escherichia coli. Escherichia coli, a versatile pathogen. 2018:181-211.
  4. Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543-75.
  5. Lei J, Sun L, Huang S, Zhu C, Li P, He J, et al. The antimicrobial peptides and their potential clinical applications. American journal of translational research. 2019;11(7):3919.
  6. Huang H-N, Pan C-Y, Chan Y-L, Chen J-Y, Wu C-J. Use of the antimicrobial peptide pardaxin (GE33) to protect against methicillin-resistant Staphylococcus aureus infection in mice with skin injuries. Antimicrobial agents and chemotherapy. 2014;58(3):1538-45.
  7. Oren Z, Shai Y. A class of highly potent antibacterial peptides derived from pardaxin, a pore‐forming peptide isolated from Moses sole fish Pardachirus marmoratus. European Journal of Biochemistry. 1996;237(1):303-10.
  8. Hallock KJ, Lee D-K, Omnaas J, Mosberg HI, Ramamoorthy A. Membrane composition determines pardaxin's mechanism of lipid bilayer disruption. Biophysical journal. 2002;83(2):1004-13.
  9. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1999;1462(1-2):55-70.
  10. Lin B, Hung A, Li R, Barlow A, Singleton W, Matthyssen T, et al. Systematic comparison of activity and mechanism of antimicrobial peptides against nosocomial pathogens. European Journal of Medicinal Chemistry. 2022;231:114135.
  11. Standards NCfCL. Performance Standards for Antimicrobial Disk Susceptibility Tests. 6th Edition, Approved Standard M2-A6 (M100-S7): National Committee for Clinical Laboratory Standards. 1997.
  12. Rajabnia M, Forghani MS, Hasani S, Bahadoram M, Mohammadi M, Barahman M. Prevalence and antibiotic resistance pattern of extended spectrum beta lactamase producing Escherichia coli isolated from urinary tract infection. Journal of Renal Injury Prevention. 2019;8(2):78-81.
  13. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. Bmj. 2016;352:h6420.
  14. Moreno-Cinos C, Sassetti E, Salado IG, Witt G, Benramdane S, Reinhardt L, et al. α-Amino diphenyl phosphonates as novel inhibitors of Escherichia coli ClpP protease. Journal of Medicinal Chemistry. 2018;62(2):774-97.
  15. Nezhadi J, Narenji H, Barhaghi MHS, Rezaee MA, Ghotaslou R, Pirzadeh T, et al. Peptide nucleic acid-mediated re-sensitization of colistin resistance Escherichia coli KP81 harboring mcr-1 plasmid. Microbial pathogenesis. 2019;135:103646.
  16. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature biotechnology. 2006;24(12):1551-7.
Archives of Razi Institute
Volume 79, Issue 5
September and October 2024
Pages 963-966

Files

Share

How to cite

Statistics